Kurebayashi, J., Kanomata, N., Moriya, T., Kozuka, Y., Watanabe, M., & Sonoo, H. (2010). Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype. BioMed Central.

Kurebayashi, Junichi, Naoki Kanomata, Takuya Moriya, Yuji Kozuka, Mika Watanabe, and Hiroshi Sonoo. Preferential Antitumor Effect of the Src Inhibitor Dasatinib Associated With a Decreased Proportion of Aldehyde Dehydrogenase 1-positive Cells in Breast Cancer Cells of the Basal B Subtype. BioMed Central, 2010.

Kurebayashi, Junichi, et al. Preferential Antitumor Effect of the Src Inhibitor Dasatinib Associated With a Decreased Proportion of Aldehyde Dehydrogenase 1-positive Cells in Breast Cancer Cells of the Basal B Subtype. BioMed Central, 2010.